Načítá se...
Cell-Based Therapies for Stroke: Are We There Yet?
Stroke is the second leading cause of death and physical disability, with a global lifetime incidence rate of 1 in 6. Currently, the only FDA approved treatment for ischemic stroke is the administration of tissue plasminogen activator (tPA). Stem cell clinical trials for stroke have been underway fo...
Uloženo v:
| Vydáno v: | Front Neurol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6603096/ https://ncbi.nlm.nih.gov/pubmed/31293500 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2019.00656 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|